Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

Summary

This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.

Timeline

Start

2006-10

Primary completion

2008-12

Completion

2012-06

Drugs

Indications